# Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ

> **NCT01501149** · PHASE4 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 80 (estimated)

## Conditions studied

- Nasal and Nasal-type NK/T-cell Lymphoma

## Interventions

- **DRUG:** DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
- **DRUG:** Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）

## Key facts

- **NCT ID:** NCT01501149
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2015-12
- **Final completion:** 2019-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2015-07-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01501149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01501149, "Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01501149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*